|
Menstrual status (Post - vs. Pre/Peri-)
|
/
|
/
|
2.33 (1.69–3.22)
|
< 0.001
|
|
Neo-adjuvant therapy (Yes vs. No)
|
2.51 (1.91–3.30)
|
< 0.001
|
2.39 (1.61–3.56)
|
< 0.001
|
|
Breast surgery (BCS vs. Mastectomy)
|
1.00 (0.77–1.30)
|
0.992
|
0.73 (0.47–1.12)
|
0.149
|
|
Tumor size (> 2.0 cm vs. ≤ 2.0 cm)
|
1.54 (1.26–1.88)
|
< 0.001
|
1.81 (1.32–2.48)
|
< 0.001
|
|
ALN status (Positive vs. Negative)
|
1.58 (1.29–1.93)
|
< 0.001
|
2.15 (1.57–2.93)
|
< 0.001
|
|
Histological grade
| |
< 0.001
| |
< 0.001
|
|
III vs. I/II
|
1.44 (1.15–1.81)
| |
1.69 (1.19–2.40)
| |
|
NA vs. I/II
|
1.58 (1.21–2.06)
| |
2.02 (1.36–3.01)
| |
|
LVI (Yes vs. No)
|
1.26 (0.90–1.75)
|
0.176
|
1.55 (0.94–2.54)
|
0.084
|
|
ER
| |
0.074
| |
< 0.001
|
|
10–49% vs. 1–9%
|
1.18 (0.72–1.94)
| |
0.95 (0.52–1.73)
| |
|
≥ 50% vs. 1–9%
|
0.89 (0.55–1.45)
| |
0.44 (0.24–0.78)
| |
|
PR (≥ 20% vs. < 20%)
|
0.82 (0.67–1.00)
|
0.050
|
0.77 (0.55–1.07)
|
0.118
|
|
Ki-67 (≥ 14% vs. < 14%)
|
1.49 (1.21–1.85)
|
< 0.001
|
1.43 (1.02–2.00)
|
0.037
|
|
Radiotherapy (Yes vs. No)
|
0.97 (0.78–1.21)
|
0.790
|
1.09 (0.74–1.59)
|
0.675
|
|
Chemotherapy (Yes vs. No)
|
1.15 (0.91–1.46)
|
0.236
|
0.94 (0.66–1.35)
|
0.744
|
|
Endocrine therapy (Yes vs. No)
|
0.56 (0.41–0.76)
|
< 0.001
|
0.46 (0.30–0.71)
|
< 0.001
|
|
Group (HER2-pos-T vs. HER2-neg)
|
0.52 (0.37–0.73)
|
< 0.001
|
0.38 (0.22–0.67)
|
0.037
|
